Please login to the form below

Not currently logged in

Novartis pays $440m for preclinical hepatitis C drug

Signs licensing deal with Enanta Pharmaceuticals for its NS5A inhibitor EDP-239

Novartis has signed a licensing deal worth up to $440m with Enanta Pharmaceuticals for a candidate hepatitis C virus (HCV) treatment that is still in preclinical testing.

The compound covered by the license is EDP-239, an inhibitor of the viral protein NS5A which has become a hot topic in hepatitis C research thanks to its apparently critical role in viral replication.

Enanta was recently granted approval by the FDA to start clinical trials of the drug and under its agreement with Novartis the Swiss pharma will now take responsibility for bringing the drug through clinical development and onto the market.

The size of the deal - which includes $34m in upfront payments - reflects the enormous interest by pharmaceutical companies in developing treatment regimens for hepatitis C that do not rely on the use of injectable interferon-based therapies

In addition to the upfront payment, US-based Enanta stands to receive up to $406m in development, regulatory and commercial milestones, as well as double-digit royalties on sales if EDP-239 reaches the market.

"Novartis is a recognised leader in the field of HCV, and access to its global expertise combined with our shared vision for commercialising HCV therapies will support the successful development and commercialisation of products targeting NS5A," said Jay Luly, Enanta's president and chief executive.

Some 170m people worldwide are affected by the virus and market researchers predict the availability of simpler, oral regimens consisting of directly-acting antivirals used in combination could expand annual HCV drug sales to more than $20bn in the coming years.

Given the scale of the opportunity it is unsurprising that Novartis has been pursuing research in hepatitis C for years, but to date the Swiss firm has not launched a product specifically to treat the disease.

At the moment its lead candidate is first-in-class cyclophilin inhibitor DEB025 (alisporivir), licensed from Swiss biotech Debiopharm, which works by blocking part of the replication process within the NS5A region. Promising phase II data on this product were presented last year.

But the addition of EDP-239 will bolster an HCV pipeline at Novartis that has seen a number of disappointments in recent years.

In 2010 the company stopped development of its long-acting interferon product albinterferon alfa-2b, and also suffered disappointments with valopicitabine, a polymerase inhibitor licensed from Idenix, as well as ANA975, a toll-like receptor 7 agonist licensed from Anadys Pharma.

At the moment the lead NS5A inhibitor coming through development is Bristol-Myers Squibb's daclatasvir (BMS-790052), which has reached phase III testing.

Compounds in earlier stages of clinical development include Achillion's ACH-2928, AstraZeneca's AZD-7295, Idenix' IDX719 and Presidio's PPI-461 and PPI-688.

22nd February 2012


Featured jobs

Subscribe to our email news alerts


Add my company
Say Communications

Influencing positive behaviours and delivering change is what drives us, using thought leadership, education, social and professional engagement and compelling,...

Latest intelligence

Theresa Heggie
Alnylam’s big moment: bringing groundbreaking RNAi drugs to Europe
Theresa Heggie talks about the biotech’s 16-year path to market, and the promise of its ‘gene silencing’ medicines...
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...